Form D · Biotechnology
Tilos Therapeutics, Inc.
Cambridge, MA · CIK 0001678508
Offering snapshot reported Sep 21, 2017 · SEC filing
- Reported sold
- $3.05M Offering amount: $4.05M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 13, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2017 | Initial | $3,050,000 | No comparison | 3 | SEC filing |
| Sep 1, 2016 | Initial | $750,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-295149
Source: Form D, filed Sep 21, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Edwards | Director, Executive |
| Barbara Fox | Director, Executive |
| Martin Heidecker | Director |
| Roger Kitterman | Director |
| Julius Knowles | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Labcentral 700 Main Street, North
Cambridge, MA, 02139
Cambridge, MA, 02139